Alpha-Galcer (KRN7000) used in hepatic research

Abnormal Changes in NKT Cells, the IGF-1 Axis, and Liver Pathology in an Animal Model of ALS

Natural killer T cells activated by a lipopeptidophosphoglycan from Entamoeba histolytica are critically important to control amebic liver abscess

Targeting the diverse immunological functions expressed by hepatic NKT cells

TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection

α-Galactosylceramide activates antitumor immunity against liver tumor

Protective Role of Interleukin-17 in Murine NKT Cell-Driven Acute Experimental Hepatitis

Sulfatide-Mediated Activation of Type II Natural Killer T Cells Prevents Hepatic Ischemic Reperfusion Injury In Mice

Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance

Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice

SOCS3 in T and NKT cells negatively regulates cytokine production and ameliorates ConA-induced hepatitis

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation

Suppression of Con A-induced hepatitis induction in ICOS-deficient mice

Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors

Preactivation of NKT cells with Alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor

Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment

Antitumor Effect of Alpha-Galactosylceramide (KRN7000) on Spontaneous Hepatic Metastases Requires Endogenous Interleukin 12 in the Liver

KRN7000 in Chronic Hepatitis B

Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection

Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production

Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with alpha-Galactosylceramide

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice

CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells

Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro

α-Galactosylceramide and Novel Synthetic Glycolipids Directly Induce the Innate Host Defense Pathway and Have Direct Activity against Hepatitis B and C Viruses

Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor

Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C

Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide

Injection of the immuno-modulatory drug alpha-galactosylceramide results in the recruitment of a large population of antigen-presenting cells into the liver of C57BL/6 mice

Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide

Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo

NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells

CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver

Back to top

 

Meet Funakoshi Company

Please visit our booth at one of these 2012 meetings:

AACR
Booth# 333
April 1-4, 2012

NIH Spring Festival
Booth# 903
April 25-26, 2012